Perminder Bhatia

Donanemab in Early Symptomatic Alzheimer Disease

John R. Sims, Jennifer A. Zimmer, Cynthia Evans et al. · JAMA · 2023 · 2.6K citations · Full text

Medicine, Neurology, Neuroscience +17

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 104 citations · Full text

Life Sciences, Neurology, Neuroscience +9

Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study

Ana Westenberger, Volha Skrahina, Tatiana Usnich et al. · Brain · 2024 · 89 citations · Full text

Life Sciences, Genetics, Neurology +15

Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study

Michael R. Sperling, Bassel Abou‐Khalil, Sami Aboumatar et al. · Epilepsia · 2021 · 69 citations · Full text

Medicine, Neurology, Pharmacotherapy +16

Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications

William E. Rosenfeld, Bassel Abou‐Khalil, Sami Aboumatar et al. · Epilepsia · 2021 · 63 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17